LONDON (ShareCast) - (Sharecast News) - Caledonia Investments said investors in portfolio company Agilytix were selling their interest to Cinven.
The company said its gross proceeds were expected to be $183m net of fees, with the cash to be held for future investment. Caledonia's shareholding in BioAgilytix was valued by Caledonia at £51m as at September 30.

The deal is subject to US anti-trust approvals and is expected to complete in December 2021.

Caledonia co-invested in BioAgilytix in February 2019 with Belgium-based investment company Cobepa and UK based specialist healthcare fund GHO Capital.

In a separate statement Cinven said Cobepa, which is BioAgilytix' current majority investor, will reinvest in the business and keep a minority stake.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE